IBRX
NasdaqIMMUNITYBIO, INC.
Basic Materials · Biological Products, (No Diagnostic Substances)
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$934,000
2021
$240,000
2022
$622,000
2023
$14.7M
2024
$113.3M
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$113.3M
Net Income$-351.5M
Gross Profit—
Oper Income$-256.0M
EPS (dil)$-0.38
Rev/sh$0.11
FCF/sh$-0.29
Book/sh$-0.48
Gross M—
Oper M-226.0%
Profit M-310.2%
FCF M-272.6%
ROE70.4%
ROA-70.0%
ROIC—
R&D/Rev167.8%
Rev Y/Y668.3%
Rev 3Y CAGR678.6%
EPS Y/Y38.7%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+31.3%
Current Ratio5.10
Quick Ratio5.08
Debt/Eq0.00
Int Coverage-4.2×
Net Debt$86.6M cash
Total Debt$1.8M
Cash & Eq$88.3M
Total Assets$501.9M
Oper CF$-304.9M
Capex$3.8M
Free CF$-308.8M
Buybacks$0
Equity$-499.6M
Liabilities$1.0B
Shs Outstand1.05B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $934,000 | $240,000 | $622,000 | $14.7M | $113.3M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-330.3M | $-351.3M | $-362.3M | $-344.2M | $-256.0M |
| Net Income | $-349.8M | $-417.3M | $-583.9M | $-413.6M | $-351.5M |
| Diluted EPS | $-0.89 | $-1.04 | $-1.15 | $-0.62 | $-0.38 |
| Operating Cash Flow | $-274.4M | $-337.5M | $-366.8M | $-391.2M | $-304.9M |
| Free Cash Flow | $-308.0M | $-415.7M | $-397.3M | $-398.1M | $-308.8M |
COMMUNITY · $IBRX0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.